Related Experiment Video
Updated: Jul 9, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Insulin use in elderly diabetic patients.
Scott K Ober1, Sharon Watts, Renée H Lawrence
1Case Western Reserve University, Louis Stokes Cleveland VAMC, 10701 East Blvd, Cleveland, OH 44106, USA. scott.ober@med.va.gov
Clinical Interventions in Aging
|November 30, 2007
Summary
Achieving tight glucose control in older adults with type 2 diabetes is vital but challenging. New insulin analogs offer a safer way to manage blood sugar and reduce complications in elderly patients.
Area of Science:
- Gerontology
- Endocrinology
- Metabolic Diseases
Background:
- Type 2 diabetes prevalence and mortality are rising in older adults.
- Tighter glucose control may reduce complications but poses hypoglycemia risks.
- Existing diabetes guidelines may not adequately address elderly patient heterogeneity.
Purpose of the Study:
- To provide guidelines for safe glycemic control in elderly patients with type 2 diabetes.
- To discuss the role of new insulin analogs in diabetes management for seniors.
- To offer practical strategies for individualizing diabetes treatment in older adults.
Main Methods:
- Review of current literature on type 2 diabetes management in the elderly.
- Discussion of the physiological function of insulin and new insulin analogs.
- Exploration of methods for matching insulin therapy with carbohydrate intake.
Main Results:
- New insulin analogs offer improved physiological matching of insulin peaks.
- These analogs may enable safer and tighter glucose control in elderly patients.
- Individualized treatment strategies are essential for effective diabetes management in this population.
Conclusions:
- Developing specific guidelines for elderly patients is crucial for reducing diabetes-related crises and complications.
- New insulin analogs represent a significant advancement in achieving safer glycemic control.
- Personalized approaches incorporating these agents can improve outcomes for older adults with diabetes.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...